Peptide Protocol
Peptide Protocol
 App Store

Selank: the complete guide

Selank is a synthetic heptapeptide modeled on tuftsin. It is studied for anxiolytic, nootropic, and immunomodulatory effects without the sedation or dependence of benzodiazepines.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassHeptapeptide anxiolytic / nootropic
Half-lifeApproximately 30 minutes systemically
Typical dose250–500 mcg intranasally, 1–3x daily
CategoryNootropic / anxiolytic
Research useAnxiety, cognition, stress-resilience research
FDA statusApproved as a prescription nasal spray in Russia; not FDA approved in the US.

How Selank works

Selank modulates GABAergic, serotonergic, and noradrenergic pathways. It also influences expression of BDNF and enkephalin-related genes.

Typical Selank dosage

Commonly reported research ranges: 250–500 mcg intranasally, 1–3x daily.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute Selank

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 300 mcg dose this works out to the unit count shown in the calculator below.

Open the Selank reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 30 minutes systemically.

This half-life informs how often Selank is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Selank stacks

Storage and handling

Lyophilized refrigerated. Reconstituted for nasal spray: refrigerated, use within 2–4 weeks.

FDA and regulatory status

Approved as a prescription nasal spray in Russia; not FDA approved in the US.

Selank clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Selank protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide modeled on tuftsin. It is studied for anxiolytic, nootropic, and immunomodulatory effects without the sedation or dependence of benzodiazepines.

How does Selank work?

Selank modulates GABAergic, serotonergic, and noradrenergic pathways. It also influences expression of BDNF and enkephalin-related genes.

What is a typical Selank dose?

Commonly reported ranges are 250–500 mcg intranasally, 1–3x daily. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Selank?

Approximately 30 minutes systemically. This influences how often it is administered.

How do you reconstitute Selank?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of Selank?

Generally well tolerated in trials; Occasional mild headache; Transient nasal irritation (intranasal route).

Is Selank FDA approved?

Approved as a prescription nasal spray in Russia; not FDA approved in the US.

Are there clinical trials for Selank?

Registered or published clinical-trial sources for Selank are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Selank literature (PubMed) — National Library of Medicine. Primary research on selank anxiolytic and GABAergic modulation
  2. Kozlovskaya et al. — Selank in anxiety disorders — PubMed. Russian clinical studies on selank anxiolytic effect
  3. Selank clinical trial records — ClinicalTrials.gov. Limited registered trials (primarily Russian development)

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.